Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses

D. Svec, S. Dolatabadi, C. Thomsen, N. Cordes, M. Shannon, P. Fitzpatrick, G. Landberg, P. Åman, A. Ståhlberg,

. 2018 ; 98 (7) : 957-967. [pub] 20180327

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

E-resources Online Full text

NLK Free Medical Journals from 2000 to 1 year ago
ProQuest Central from 2000-01-01 to 2022-12-31
Open Access Digital Library from 2000-01-01
Open Access Digital Library from 2000-01-01
Health & Medicine (ProQuest) from 2000-01-01 to 2022-12-31
Public Health Database (ProQuest) from 2000-01-01 to 2022-12-31

FUS-DDIT3 belongs to the FET (FUS, EWSR1, and TAF15) family of fusion oncogenes, which collectively are considered to be key players in tumor development. Even though over 90% of all myxoid liposarcomas (MLS) have a FUS-DDIT3 gene fusion, there is limited understanding of the signaling pathways that regulate its expression. In order to study cell proliferation and FUS-DDIT3 regulation at mRNA and protein levels, we first developed a direct cell lysis approach that allows DNA, mRNA, and protein to be analyzed in the same sample using quantitative PCR, reverse transcription quantitative qPCR and proximity ligation assay, respectively. We screened 70 well-characterized kinase inhibitors and determined their effects on cell proliferation and expression of FUS-DDIT3 and FUS at both mRNA and protein levels in the MLS 402-91 cell line, where twelve selected inhibitors were evaluated further in two additional MLS cell lines. Both FUS-DDIT3 and FUS mRNA expression correlated with cell proliferation and both transcripts were co-regulated in most conditions, indicating that the common 5' FUS promotor is important in transcriptional regulation. In contrast, FUS-DDIT3 and FUS protein levels displayed more cell line dependent expression. Furthermore, most JAK inhibitors caused FUS-DDIT3 downregulation at both mRNA and protein levels. In conclusion, defining factors that regulate FUS-DDIT3 expression opens new means to understand MLS development at the molecular level.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19028496
003      
CZ-PrNML
005      
20190823092835.0
007      
ta
008      
190813s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41374-018-0046-3 $2 doi
035    __
$a (PubMed)29588491
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Svec, David $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden. Laboratory of gene expression, Institute of Biotechnology AS CR, BIOCEV, Prumyslova 595, 252 50, Vestec by Prague, Czech Republic.
245    10
$a Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses / $c D. Svec, S. Dolatabadi, C. Thomsen, N. Cordes, M. Shannon, P. Fitzpatrick, G. Landberg, P. Åman, A. Ståhlberg,
520    9_
$a FUS-DDIT3 belongs to the FET (FUS, EWSR1, and TAF15) family of fusion oncogenes, which collectively are considered to be key players in tumor development. Even though over 90% of all myxoid liposarcomas (MLS) have a FUS-DDIT3 gene fusion, there is limited understanding of the signaling pathways that regulate its expression. In order to study cell proliferation and FUS-DDIT3 regulation at mRNA and protein levels, we first developed a direct cell lysis approach that allows DNA, mRNA, and protein to be analyzed in the same sample using quantitative PCR, reverse transcription quantitative qPCR and proximity ligation assay, respectively. We screened 70 well-characterized kinase inhibitors and determined their effects on cell proliferation and expression of FUS-DDIT3 and FUS at both mRNA and protein levels in the MLS 402-91 cell line, where twelve selected inhibitors were evaluated further in two additional MLS cell lines. Both FUS-DDIT3 and FUS mRNA expression correlated with cell proliferation and both transcripts were co-regulated in most conditions, indicating that the common 5' FUS promotor is important in transcriptional regulation. In contrast, FUS-DDIT3 and FUS protein levels displayed more cell line dependent expression. Furthermore, most JAK inhibitors caused FUS-DDIT3 downregulation at both mRNA and protein levels. In conclusion, defining factors that regulate FUS-DDIT3 expression opens new means to understand MLS development at the molecular level.
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a DNA $x analýza $x genetika $x metabolismus $7 D004247
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a myxoidní liposarkom $x genetika $x metabolismus $7 D018208
650    _2
$a fúzní onkogenní proteiny $x analýza $x genetika $x metabolismus $7 D015514
650    _2
$a messenger RNA $x analýza $x genetika $x metabolismus $7 D012333
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dolatabadi, Soheila $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
700    1_
$a Thomsen, Christer $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
700    1_
$a Cordes, Nicole $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
700    1_
$a Shannon, Mark $u Genetic Sciences Division, Thermo Fisher Scientific, 180 Oyster Point Blvd., South San Francisco, CA, 94080, USA.
700    1_
$a Fitzpatrick, Paul $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
700    1_
$a Landberg, Göran $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
700    1_
$a Åman, Pierre $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden.
700    1_
$a Ståhlberg, Anders $u Sahlgrenska Cancer Center, Department of Pathology and Genetics, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Medicinaregatan 1F, 413 90, Gothenburg, Sweden. anders.stahlberg@gu.se. Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden. anders.stahlberg@gu.se. Department of Clinical Pathology and Genetics, Sahlgrenska University Hospital, 413 45, Gothenburg, Sweden. anders.stahlberg@gu.se.
773    0_
$w MED00003111 $t Laboratory investigation; a journal of technical methods and pathology $x 1530-0307 $g Roč. 98, č. 7 (2018), s. 957-967
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29588491 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190813 $b ABA008
991    __
$a 20190823093050 $b ABA008
999    __
$a ok $b bmc $g 1433645 $s 1066956
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 98 $c 7 $d 957-967 $e 20180327 $i 1530-0307 $m Laboratory investigation $n Lab Invest $x MED00003111
LZP    __
$a Pubmed-20190813

Find record

Citation metrics

Logged in users only

Archiving options

Loading data ...